Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study

Clinical Cancer Research - Tập 28 Số 13 - Trang 2762-2770 - 2022
Vivek Subbiah1, Irene Braña2, Alessandra Longhi3, Valentina Boni4, Jean‐Pierre Delord5, Ahmad Awada6, Pascaline Boudou‐Rouquette7, John Sarantopoulos8, Geoffrey I. Shapiro9, Anthony Elias10, Ravin Ratan1, Cristian Fernández11, Carmen Kahatt11, Martín Cullell-Young11, Mariano Siguero11, Ali Zeaiter11, Sant P. Chawla12
11The University of Texas MD Anderson Cancer Center, Houston, Texas.
22Hospital Universitari Vall d'Hebron, Barcelona, Spain.
33Istituti Ortopedici Rizzoli, Bologna, Italy.
44START Madrid–Centro Integral Oncológico Clara Campal, Hospital Universitario Madrid Sanchinarro, Madrid, Spain.
55Institut Claudius Regaud, Toulouse, France.
66Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
77Hôpital Cochin, Paris, France.
88Cancer Therapy & Research Center, San Antonio, Texas.
99Dana-Farber Cancer Institute, Boston, Massachusetts.
1010University of Colorado Cancer Center, Aurora, Colorado.
1111PharmaMar, Colmenar Viejo, Madrid, Spain.
1212Sarcoma Oncology Center, Santa Monica, California.

Tóm tắt

Abstract Purpose: Lurbinectedin suppresses the oncogenic transcription factor EWS-FLI1 through relocalization to the nucleolus, and delays tumor growth in mice bearing Ewing sarcoma xenografts. On the basis of this rationale, lurbinectedin was evaluated in patients with relapsed Ewing sarcoma. Patients and Methods: This open-label, single-arm, Basket phase II trial included a cohort of 28 treated adult patients with confirmed Ewing sarcoma, measurable disease as per Response Evaluation Criteria In Solid Tumors (RECIST) v.1.1, Eastern Cooperative Oncology Group performance status ≤2, adequate organ function, no central nervous system metastasis, and pretreated with ≤2 chemotherapy lines for metastatic/recurrent disease. Patients received lurbinectedin 3.2 mg/m2 as a 1-hour infusion every 3 weeks. Primary endpoint was overall response rate (ORR) as per RECIST v.1.1. Secondary endpoints included time-to-event parameters and safety profile. Results: ORR was 14.3% [95% confidence interval (CI), 4.0%–32.7%], with median duration of response of 4.2 months (95% CI, 2.9–5.5 months). Median progression-free survival was 2.7 months (95% CI, 1.4–4.3 months), clinical benefit rate was 39.3%, and disease control rate was 57.1%. With 39% censoring, median overall survival was 12.0 months (95% CI, 8.5–18.5 months). Most common grade 3/4 adverse events were neutropenia (57%), anemia, thrombocytopenia, and treatment-related febrile neutropenia (14% each). No deaths or discontinuations were due to toxicity. Conclusions: Lurbinectedin was active in the treatment of relapsed Ewing sarcoma and had a manageable safety profile. Lurbinectedin could represent a valuable addition to therapies for Ewing sarcoma, and is currently being evaluated in combination with irinotecan in advanced Ewing sarcoma in a phase Ib/II trial.

Từ khóa


Tài liệu tham khảo

Subbiah, 2009, Ewing's sarcoma: standard and experimental treatment options, Curr Treat Options Oncol, 10, 126, 10.1007/s11864-009-0104-6

Raney, 1997, Ewing's sarcoma of soft tissues in childhood: a report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991, J Clin Oncol, 15, 574, 10.1200/JCO.1997.15.2.574

Esiashvili, 2008, Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data, J Pediatr Hematol Oncol, 30, 425, 10.1097/MPH.0b013e31816e22f3

Subbiah, 2011, Targeted therapy of Ewing's sarcoma, Sarcoma, 2011, 686985, 10.1155/2011/686985

Womer, 2012, Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group, J Clin Oncol, 30, 4148, 10.1200/JCO.2011.41.5703

Granowetter, 2009, Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study, J Clin Oncol, 27, 2536, 10.1200/JCO.2008.19.1478

Fuchs, 2003, Complications in long-term survivors of Ewing sarcoma, Cancer, 98, 2687, 10.1002/cncr.11891

Bernstein, 2006, Ewing's sarcoma family of tumors: current management, Oncologist, 11, 503, 10.1634/theoncologist.11-5-503

Leavey, 2007, Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence, J Clin Oncol, 25, Abstract 10011, 10.1200/jco.2007.25.18_suppl.10011

Subbiah, 2012, Ewing's sarcoma: overcoming the therapeutic plateau, Discov Med, 13, 405

Cuevas, 2000, Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B, Org Lett, 2, 2545, 10.1021/ol0062502

Bueren-Calabuig, 2011, Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumor drugs: insight from molecular dynamics simulations, Nucleic Acids Res, 39, 8248, 10.1093/nar/gkr512

Harlow, 2016, Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus, Cancer Res, 76, 6657, 10.1158/0008-5472.CAN-16-0568

Santamaria Nunez, 2016, Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells, Mol Cancer Ther, 15, 1, 10.1158/1535-7163.MCT-16-0172

Leal, 2010, PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo antitumor activity, Br J Pharmacol, 161, 1099, 10.1111/j.1476-5381.2010.00945.x

Singh, 2021, FDA approval summary: lurbinectedin for the treatment of metastatic small cell lung cancer, Clin Cancer Res, 27, 2378, 10.1158/1078-0432.CCR-20-3901

Dileo, 2007, Trabectedin (T) in metastatic Ewing's family tumors (EFT) patients (pts) progressing after standard chemotherapy, J Clin Oncol, 25, Abstract 10040, 10.1200/jco.2007.25.18_suppl.10040

Harlow, 2013, Identification of ET-743 analogs with improved selectivity and potency for EWS-FLI1 and Ewing sarcoma cells, Cancer Res, 73, Abstract 2760, 10.1158/1538-7445.AM2013-2760

Harlow, 2014, PM01183 shows an improved therapeutic index relative to trabectedin and suppresses EWS/FLI1 activity at clinically achievable concentrations, Cancer Res, 74, Abstract 3962, 10.1158/1538-7445.AM2014-3962

Taamma, 2001, Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors, J Clin Oncol, 19, 1256, 10.1200/JCO.2001.19.5.1256

Elez, 2014, First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors, Clin Cancer Res, 20, 2205, 10.1158/1078-0432.CCR-13-1880

Eisenhauer, 2009, New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026

National Cancer Institute, 2009, Common Terminology Criteria for Adverse Events v.4.0 (CTCAE)

Saylors, 2001, Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study, J Clin Oncol, 19, 3463, 10.1200/JCO.2001.19.15.3463

McTiernan, 2006, High-dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumors, Ann Oncol, 17, 1301, 10.1093/annonc/mdl108

Hunold, 2006, Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors, Pediatr Blood Cancer, 47, 795, 10.1002/pbc.20719

Wagner, 2007, Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma, Pediatr Blood Cancer, 48, 132, 10.1002/pbc.20697

Casey, 2009, Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan Kettering experience, Pediatr Blood Cancer, 53, 1029, 10.1002/pbc.22206

Raciborska, 2013, Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma, Pediatr Blood Cancer, 60, 1621, 10.1002/pbc.24621

Nitschke, 1998, Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study, J Pediatr Hematol Oncol, 20, 315, 10.1097/00043426-199807000-00006

Cote, 2020, Lurbinectedin in combination with irinotecan in patients (PTS) with soft tissue sarcomas (STS)

Trigo, 2020, Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase II basket trial, Lancet Oncol, 21, 645, 10.1016/S1470-2045(20)30068-1

Gaillard, 2021, Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: a multicenter, randomized, controlled, open-label phase III study (CORAIL), Gynecol Oncol, 163, 237, 10.1016/j.ygyno.2021.08.032

Riggi, 2021, Ewing's sarcoma, N Engl J Med, 384, 154, 10.1056/NEJMra2028910

Thông tin
Thông tin xuất bản

Clinical Cancer Research

Tập 28 Số 13

2762-2770

Thông tin tác giả